Analyst Explains Why He’s Investing in This Top Biotech ETF
“But this is a subsector that’s been under the mat for quite some time. So it’s nice to see some price action there. So couple things for me.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bronte Capital John Hempton | 69,265 | $11,695,395 | -5% | 1.16% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 666,343 | $112,512,008 | 0.15% | |
| 2. | 648,103 | $109,439,535 | 2.64% | |
| 3. | 142,013 | $23,978,815 | 5.94% | |
| 4. | 132,371 | $22,350,796 | 0.03% | |
| 5. | 120,147 | $20,286,892 | 1.31% |